- Home
- SRTS vs KPTI Comparison
SRTS vs KPTI Comparison
Compare SRTS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- KPTI
- Stock Information
- Founded
- SRTS 2010
- KPTI 2008
- Country
- SRTS United States
- KPTI United States
- Employees
- SRTS N/A
- KPTI N/A
- Industry
- SRTS Medical/Dental Instruments
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- KPTI Health Care
- Exchange
- SRTS Nasdaq
- KPTI Nasdaq
- Market Cap
- SRTS 51.8M
- KPTI 44.5M
- IPO Year
- SRTS 2016
- KPTI 2013
- Fundamental
- Price
- SRTS $3.45
- KPTI $5.90
- Analyst Decision
- SRTS Strong Buy
- KPTI Buy
- Analyst Count
- SRTS 3
- KPTI 6
- Target Price
- SRTS $8.00
- KPTI $39.80
- AVG Volume (30 Days)
- SRTS 88.0K
- KPTI 242.6K
- Earning Date
- SRTS 11-13-2025
- KPTI 11-04-2025
- Dividend Yield
- SRTS N/A
- KPTI N/A
- EPS Growth
- SRTS N/A
- KPTI N/A
- EPS
- SRTS N/A
- KPTI N/A
- Revenue
- SRTS $37,564,000.00
- KPTI $137,269,000.00
- Revenue This Year
- SRTS N/A
- KPTI $3.40
- Revenue Next Year
- SRTS $46.14
- KPTI $9.69
- P/E Ratio
- SRTS N/A
- KPTI N/A
- Revenue Growth
- SRTS 3.29
- KPTI N/A
- 52 Week Low
- SRTS $3.03
- KPTI $3.51
- 52 Week High
- SRTS $9.33
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- SRTS 56.63
- KPTI 33.94
- Support Level
- SRTS $3.11
- KPTI $6.08
- Resistance Level
- SRTS $3.68
- KPTI $6.68
- Average True Range (ATR)
- SRTS 0.12
- KPTI 0.64
- MACD
- SRTS 0.09
- KPTI -0.19
- Stochastic Oscillator
- SRTS 75.32
- KPTI 2.95
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.